ClinicalTrials.gg
CompletedNCT07770789Updated Aug 18, 2026

Clinical Trial to Study the Efficacy and Safety of Rejeunesse Shape With Lidocaine (HA Filler) in Treating Healthy Subjects

A Phase 3 interventional study of Rejeunesse and Restylane Perlane in Nasolabial Fold Correction, sponsored by Forest Hills Lab. Completed. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Forest Hills Lab · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 10 years 5 months after the study started (first participant enrolled Feb 2016, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Study summary

Intend to prove the non-inferiority of Rejeunesse against the comparing medical device of Restylane Perlane in terms of improvement, efficacy, and safety of nasolabial fold on the face

02

Conditions studied

  • Nasolabial Fold Correction
03

In context

Lead sponsor

Forest Hills Lab is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women aged more than 30 but less than 60;
  2. Those with score 3 or 4 in the wrinkle severity rating scale (WSRS) among those who want the improvement of nasolabial folds;
  3. Those with visually symmetrical with nasolabial folds;
  4. Those who agree with the suspension of all the dermatological treatment including the improvement of wrinkle on the face during the clinical study;
  5. Those who are able to read and follow instructions and participate during the entire period of clinical study;
  6. Those who decide to participate in the clinical study on their wills and agree with the subject-agreement written form.

Exclusion criteria

Exclusion Criteria:

  1. Those with skin sensitiveness on the clinical medical devices according to the result of intradermal test in the screening period;
  2. Those who were administered with the antithrombotic (I00mg, up to 300mg/day) or anti- anti-inflammatory within 2 days from the screening;
  3. Those taking the antithrombotic (low-capacity aspirin (100mg, up to 300mg/day) excluded) during the clinical study or abnormal blood coagulation or liver function;
  4. Those who have used or are scheduled to use the part ointment on the facial surface within 4 weeks from the screening date (steroid, retinoid: only for the medicines and not the cosmetics);
  5. Those treated for the improvement of wrinkle or pimp within 6 months from the screening date;
  6. Those treated for improvement of wrinkle by using collagen or hyaluronic acid filler within 6 months from the screening date or decortication, skin regeneration treatment, or plastic surgery on the facial surface (including botox wrinkle treatment);
  7. Those treated with application of clinical medical devices for CaHA (Calcium Hydroxy Apatite) within a year from the screening date;
  8. Those inserted with permanent skin extending implant such as soft form or silicon on the facial surface
  9. Those in need of treatment on facial surface but with scar not treated for more than a year or with scar on the areas applied with clinical medical devices;
  10. Those with the history of anaphylaxis or sever complex allergy symptoms;
  11. Those with history of hypertropic scar or keloid medical history;
  12. Those with side effect on the EMLA cream in the past (NIA for the criteria of exclusion for subjects who are not to use the EMLA cream);
  13. Those with skin problem or infection from cut influencing on this clinical study;
  14. Those with degraded immune function;
  15. Those with clinically serious problem on cardiovascular system, digestive system, respiratory system, endocrine system, and central nervous system or mental disease that significantly influences on this clinical study;
  16. Those participating in other clinical studies within 30 days from the screening date;
  17. Those who did not agree to participate in the in the medically allowed methods among female subjects who are able to be pregnant during the clinical study; * Medically allowed contraception method: Condom, oral contraception for more than 6 months, cases of using shot or inserting anti-conceptive or installing conceptive device in the womb;
  18. Pregnant women or lactating women;
  19. Other than aforementioned subjects, those with clinical opinion regarding them as inappropriate subjects in this study from the medical judgment from charging person or manager of this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
71 participants (actual)

Study arms

  • Placebo comparator
    Restylane Perlane Control Group

    Device: Rejeunesse

  • Experimental
    Rejeunesse

    Device: Restylane Perlane

Interventions

  • DeviceRejeunesse

    The clinical medical device, Rejeunesse, is a cross-lined HA hydrogel made by using the cross-linker of 1, 4-butandiol diglycidyl ether (BDDE) with low toxicity from sodium hyaluronate derived from microorganisms. It is a tissue repair biological material in a gel type injected to the skin (thick skin - epidermis and surface of thick skin) near wrinkles on the face for the temporary improvement of wrinkles.

  • DeviceRestylane Perlane

    Restylane Perlane selected as the control group is non-animal stabilized hyaluronic acid (NASHA) originating from bacterial fermentation. It is a tissue repair biomaterial for soft skin \[3\]. Restylane Perlane is widely used for wrinkle treatment, indented areas and other beauty purposes. Products used in this clinical study can be applied to all types of wrinkles on the face. Stabilized HA constituting the Restylane Perlane is slowly absorbed in the body after combining with water molecules in the skin tissue and is completely absorbed in the skin as a biodegradable substance. Therefore, no residue is left in the body.

06

What researchers measure

Primary outcomes

  1. Primary Endpoint Variables

    Verify the average value of the difference between Wrinkle Severity Rating Scale (WSRS) between control group and experiment group assessed by the independent evaluator on the 24th week after the final application of medical devices for clinical study Compare the average value of WSRS between control group and experiment group assessed by the independent evaluator on the 24th week after the final application of clinical medical devices. The WSRS is a 5 point scale with 1 being no wrinkles and 5 being extreme wrinkles.

    Time frame: 24th week after the final application of medical devices for clinical study and assess WSRS.

Secondary outcomes

  1. Average value of Visual Analogue Scale (VAS) between the experiment group and control group within 60 minutes after the final application of clinical medical devices.

    Make sure to evaluate the degree of pain on a scale from 0 to 10 that subjects feel in the operation when applying or immediately after applying the clinical medical devices. The Visual Analogue Scale (VAS) is the record of the severest pain on the one side while recording that there is no pain on the other side in the 10cm length of line. 0 is "no pain" and 10 is worst pain possible.

    Time frame: 60 minutes after the final application of clinical medical devices

  2. Average value of Wrinkle Severity Rating Scale (WSRS) between the experiment group and control group on the 8th week after the final application of clinical medical devices.

    Compare the Wrinkle Severity Rating Scale (WSRS) average value between experiment group and control group assessed by the independent evaluator on the 8th week after the final application of clinical medical devices. The WSRS is a 5 point scale with 1 being no wrinkles and 5 being extreme wrinkles.

    Time frame: 8th week after the final application of clinical medical devices

  3. Average value of global aesthetic improvement scale (GAIS) between control and experiment group assessed by the investigators on the 8th and 24th week after the final application of medical devices before the initial application of medical devices

    Compare the average value of GAIS assessed by each investigator on the 8th and 24th week after the final application compared to before the initial application of clinical medical devices

    Time frame: 8th and 24th week after the final application of medical devices before the initial application of medical devices.

  4. Average value of Global Aesthetic Improvement Scale (GAIS) between control group and experiment group assessed by the investigators on the 8th and 24th week after the final application of medical devices before the initial application of medical devices

    Compare the average value of Global Aesthetic Improvement Scale (GAIS) assessed by each investigator on the 8th and 24th week after the final application compared to before the initial application of clinical medical devices. The Global Aesthetic Improvement Scale is a 5 point scale that goes from -1: worse, 0: no change, 1: improved, 2: much improved and 3: very much improved.

    Time frame: 8th and 24th week after the final application compared to before the initial application of clinical medical devices

  5. Proportion of changes in wrinkle severity rating scale (WSRS) between control group and experiment group on the 24th week after the final application of medical devices compared to before the initial application of medical devices

    Compare the control group and experiment group in terms of proportion of WSRS changes assessed by the independent evaluator on the 24th week after the final application compared to before the initial application of clinical medical devices.

    Time frame: 24th week after the final application compared to before the initial application of clinical medical devices.

  6. Proportion of changes in wrinkle severity rating scale (WSRS) in the experiment group and control group on the 24'h week after the final application of medical devices prior to the initial application of medical devices assessed by the investigator.

    Compare the control group and experiment group on the changes in WSRS value assessed by the investigator on the 24th week after the application in comparison to before the initial application of clinical medical devices

    Time frame: 24th week after the application in comparison to before the initial application of clinical medical devices

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Sep 2016, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 18, 2026
StartActual
Feb 15, 2016
Primary completionActual
Sep 12, 2016
CompletionActual
Nov 29, 2016
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07770789
Lead sponsor
Forest Hills Lab
Collaborators
New Medic Corporation, Sumin D&C
Responsible party
Sponsor
First posted
Aug 18, 2026
Start date
Feb 15, 2016
Primary completion
Sep 12, 2016
Completion
Nov 29, 2016
Last update
Aug 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion